Atalanta Sosnoff Capital, LLC Vertex Pharmaceuticals Inc Transaction History

Atalanta Sosnoff Capital, LLC

$4.63 Billion
Q3 2024

A detailed history of Atalanta Sosnoff Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Atalanta Sosnoff Capital, LLC holds 119,438 shares of VRTX stock, worth $51.1 Million. This represents 1.2% of its overall portfolio holdings.

Number of Shares

119,438

Previous 161,255 25.93%

Holding current value

$51.1 Million

Previous $75.6 Million 26.51%

% of portfolio

1.2%

Previous 1.7%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $19.2 Million - $21.2 Million	-41,817 Reduced 25.93%	119,438 $55.5 Million
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $2.67 Million - $3.3 Million	-6,800 Reduced 4.05%	161,255 $75.6 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $3.1 Million - $3.39 Million	-7,606 Reduced 4.33%	168,055 $70.2 Million
Q4 2023 Feb 12, 2024	BUY	$343.0 - $410.68 $18.5 Million - $22.2 Million	54,043 Added 44.44%	175,661 $71.5 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $932,362 - $999,302	-2,757 Reduced 2.22%	121,618 $42.3 Million
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $1.02 Million - $1.14 Million	3,242 Added 2.68%	124,375 $43.8 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $2.52 Million - $2.88 Million	8,899 Added 7.93%	121,133 $38.2 Million
Q4 2022 May 22, 2023	SELL	$285.76 - $321.48 $2.54 Million - $2.86 Million	-8,899 Reduced 7.35%	112,234 $32.4 Million
Q4 2022 Feb 09, 2023	SELL	$285.76 - $321.48 $3.26 Million - $3.67 Million	-11,420 Reduced 9.24%	112,234 $32.4 Million
Q3 2022 Oct 12, 2022	BUY	$273.83 - $305.53 $33.9 Million - $37.8 Million	123,654 New	123,654 $35.8 Million
Q2 2020 Jul 21, 2020	SELL	$225.48 - $295.8 $16.1 Million - $21.1 Million	-71,310 Closed	0 $0
Q1 2020 Apr 16, 2020	SELL	$199.77 - $247.81 $306,646 - $380,388	-1,535 Reduced 2.11%	71,310 $17 Million
Q4 2019 Jan 23, 2020	SELL	$166.71 - $223.91 $22.9 Million - $30.7 Million	-137,136 Reduced 65.31%	72,845 $16 Million
Q3 2019 Oct 15, 2019	SELL	$166.23 - $187.09 $1.02 Million - $1.15 Million	-6,134 Reduced 2.84%	209,981 $35.6 Million
Q2 2019 Jul 15, 2019	SELL	$164.61 - $190.37 $1.16 Million - $1.34 Million	-7,019 Reduced 3.15%	216,115 $39.6 Million
Q1 2019 Apr 09, 2019	SELL	$163.73 - $194.7 $13.5 Million - $16 Million	-82,338 Reduced 26.95%	223,134 $41 Million
Q4 2018 Jan 09, 2019	SELL	$151.91 - $192.21 $205,230 - $259,675	-1,351 Reduced 0.44%	305,472 $50.6 Million
Q3 2018 Oct 10, 2018	SELL	$167.73 - $192.74 $88,393 - $101,573	-527 Reduced 0.17%	306,823 $59.1 Million
Q2 2018 Jul 11, 2018	SELL	$145.72 - $169.96 $37.5 Million - $43.8 Million	-257,433 Reduced 45.58%	307,350 $52.2 Million
Q1 2018 Apr 06, 2018	BUY	$151.6 - $177.13 $14.2 Million - $16.6 Million	93,641 Added 19.88%	564,783 $92 Million
Q4 2017 Jan 09, 2018	BUY	$137.28 - $155.55 $11.2 Million - $12.7 Million	81,541 Added 20.93%	471,142 $70.6 Million
Q3 2017 Oct 10, 2017	BUY	$148.13 - $162.24 $57.7 Million - $63.2 Million	389,601	389,601 $59.2 Million

Others Institutions Holding VRTX

# of Institutions

1,710

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $110B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atalanta Sosnoff Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atalanta Sosnoff Capital, LLC with notifications on news.

Account

Atalanta Sosnoff Capital, LLC Vertex Pharmaceuticals Inc Transaction History